No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
RemeGen Co., Ltd. (HKG:9995) Held Back By Insufficient Growth Even After Shares Climb 25%
[Brokerage Focus] Zhongtai International gives remegen (09995) an initial "buy" rating, expecting the shareholders' net loss to narrow year by year.
Jinwu Financial News | Zhongtai International released research reports indicating that remegen (09995) has three major technology platforms: antibody-drug conjugates (ADC), fusion proteins, and bispecific antibodies. The first domestically produced ADC, Weidixitun monoclonal antibody (Aidiqi), was launched in 2021, and the fusion protein Taitaxip (Tai'ai) is the world's first biopharmaceutical for treating systemic lupus erythematosus with two target points. These two products are star products in the domestic oncology and autoimmune fields. The company has six drugs in research in the oncology and ophthalmology fields, and its R&D pipeline is robust. The firm asserts that the sales revenue of the company's first domestically produced ADC, Weidixitun monoclonal antibody, will increase rapidly; Taitaxip will benefit from.
[Brokerage Focus] Zhongtai Securities maintains a 'shareholding' rating for Remegen (09995), indicating a significant improvement in its third-quarter profitabilty both year-on-year and quarter-on-quarter.
Kingu Financial News | Zhongtai Securities issued a research report, remegen (09995) recorded a third-quarter revenue of 0.47 billion yuan, a growth of +34.6% compared to the same period last year; total revenue for January-September 2024 was 1.21 billion yuan, a 57.10% growth year-on-year; net income in the third quarter was a loss of 0.29 billion yuan, a 32.6% decrease in losses compared to the second quarter. The bank pointed out that Tai Tesip and Videsituximab's high-quality academic research results continue to be published in international societies and journals, accumulating evidence-based medicine to promote the continued growth in sales domestically, with revenue in the first three quarters maintaining robust and rapid growth, in line with expectations. 20
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
